PSS8 Pharmacoepidemiology of Cellular/Tissue Derived Products for the Treatment of Venous Leg Ulcers in Outpatient Care Settings  by Gilligan, A.M. & Waycaster, C.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A605
PSS9
The ePidemiology of medical TreaTmenT for glaucoma and ocular 
hyPerTenSion in germany
Ernst F.
Santen GmbH, Munich, Germany
Objectives: The purpose of this study is to review the epidemiology and the treat-
ment paradigm of German glaucoma population and to assess the frequency of 
switches from monotherapy to second- or third line combination therapy in primary 
open angle glaucoma (POAG) patients. Glaucoma is the second leading cause of 
blindness globally. The newly published EGS guidelines state that if the first choice 
monotherapy is well tolerated and has effective intra ocular pressure (IOP) lowering 
but has not succeeded in reaching the target pressure, the addition of a second drug 
should be considered. MethOds: German patient databases were searched in the 
following areas: glaucoma prevalence and incidence studies in German popula-
tion as well as treatment paradigm in glaucoma patients. Results: Our analysis 
underlines the high number of glaucoma patients in Germany and the relevance of 
this disease for the German health care system. The study also demonstrates that 
a considerable number of glaucoma patients do not reach IOP target under mono-
therapy and have to be treated with a combination therapy. In general, treatment 
with a combination of agents of different classes is associated with superior IOP 
lowering efficacy. With an increasing number of available fixed dose combination 
products, more options become available for combination therapy of glaucoma 
patients. cOnclusiOns: Glaucoma care needs to be given high priority in public 
health programs. Especially treatment options for glaucoma patients in need for a 
combination therapy should be in the focus of health care system decision makers 
as well as further research in glaucoma clinical trials and clinical care.
SenSory SySTemS diSorderS – cost Studies
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a uS hoSPiTal economic imPacT model for oriTavancin in abSSSi 
PaTienTS WiTh riSk of mrSa infecTionS
Wu C.1, Fortier K.J.1, LaPensee K.2, Fan W.2, Mitchell M.2, Cyr P.L.1, Jensen I.S.1
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Objectives: It is estimated that acute bacterial skin and skin structure infections 
(ABSSSI) account for about 10% of hospital admissions in the US. Analyses of hos-
pital claims indicate 74% of ABSSSI admissions involve empiric treatment with 
methicillin-resistant Staphylococcus aureus (MRSA) active antibiotics. Hospitalization 
costs could be reduced if moderate-severe ABSSSI patients were treated to a greater 
extent in the observational unit followed by discharge to outpatient parenteral 
antibiotic therapy (OPAT). Oritavancin is a novel single-dose regimen, intrave-
nous lipoglycopeptide antibiotic for ABSSSIs caused by gram-positive bacteria, 
including MRSA. The aim of our analysis was to quantify the economic value of 
using oritavancin for ABSSSI patients at risk of MRSA from a US hospital perspec-
tive. MethOds: A decision analytic model based on current clinical practice was 
developed to estimate the economic value of decreased hospital resources by using 
oritavancin. Utilization of antibiotics was informed by analysis of the Premier hos-
pital database. Demographic and clinical data were derived from a targeted litera-
ture review. ER, observation, laboratory, administration costs were from Medicare 
National Limitation amounts. Drug costs were 2014 wholesale acquisition costs. To 
estimate the economic impact of reducing resources using oritavancin we set its 
price to $0. Results: For a hypothetical US hospital treating 1,000 ABSSSI patients 
eligible for IV MRSA antibiotics/year, the administration of oritavancin in 25.75% of 
patients facilitates shifting patients to the OPAT setting (441 to 561 patients) with 
a total annual economic impact of $2,752K. Inpatient and outpatient costs were 
reduced by $2,543K and $209K, respectively. Inpatient cost savings were derived from 
a reduction in hospitalizations and lower administration burden drove decreased 
OPAT costs. cOnclusiOns: Using oritavancin in moderate-severe ABSSSI patients, 
including those at risk of MRSA, is estimated to deliver an estimated cost reduc-
tion of $2,752/patient by shifting patient care to the OPAT setting, and decreasing 
resource utilization.
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economic imPacT of viSual imPairmenT: a PiloT STudy in SingaPore
Wang X.1, Luo N.2, Lamoureux E.3, Ang M.4
1National University of Singapore, Singapore, 2Saw Swee Hock School of Public Health, National 
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National Eye Center, Singapore
Objectives: To examine the economic impact and independent determinants of 
visual impairment (VI) in Singapore. MethOds: 100 patients with VI associated 
with the most common eye diseases were recruited from the Singapore National Eye 
Centre. VI was classified as mild and moderate/severe VI based on the presenting 
visual acuity (VA) in the better-seeing eye. Medical costs (MC) and loss of productiv-
ity (LP) in the patients and their families were estimated based on the center’s billing 
data and self-reported data, respectively. LP was calculated for working patients 
based on absenteeism due to VI. Linear regression models were used to assess the 
association between costs and VI, generic (EQ-5D), and vision-specific quality of 
life (VF-14). Results: The median (range) age of participants was 73.0 years old 
(47.0-92.0). The proportion of male was 48.0% and the median (range) presenting 
VA was 0.54 (0.30-2.00). The yearly median (range) MC and LP were S$1.53K (S$0.13-
S$83.59K) and S$0 (S$0-S$7.62K) per person, respectively. The yearly MC for those 
with mild VI (S$3.50K) was significantly lower than those with moderate/severe VI 
(S$5.21K) (P< 0.0001). The yearly MC in participants reporting full health or better 
vision function were lower than those not in full health or better vision function 
(e. g. MC for participants in full health= S$2.96K; MC for participants not in full 
health= S$5.19K; P< 0.0001). After adjusting for socio-demographic characteristics, 
the association between MC and VI, EQ-5D and VF-14 remained the same. LP had a 
similar association with EQ-5D and VF-14 with or without adjustment; however, LP 
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clinical effecTiveneSS of fumaric acid eSTerS (fumaderm) in 
PSoriaSiS: a SySTemaTic revieW of liTeraTure
Ceglowska U., Wlodarczyk A., Slomka M.
Agency for Health Technology Assessment In Poland (AHTAPol), Warsaw, Poland
Objectives: To review the literature evaluating the clinical efficacy of Fumaderm 
(FAE) in patients suffering from psoriasis and psoriatic arthritis. MethOds: 
Systematic literature search in electronic databases (MEDLINE, Cochrane and 
Embase) was performed (from inception to March 14,2014). Results were presented 
by narrative synthesis including a quality assessment using Jadad scale. Results: 
Three randomized controlled trials were included (Fallah Arani 2011, Altmeyer 1994, 
Peeters 1992). Quality of studies ranged from 3 to 4 points. Observation period 
was 16 weeks for all studies. One open-label study comparing FAE with metho-
trexate (MTX) in moderate to severe chronic plaque psoriasis was identified. The 
primary efficacy endpoint was the difference in mean change from baseline in 
Psoriasis Area and Severity Index (PASI). After 12 weeks of treatment the mean 
PASI (± SD) decreased to 10.5 ± 6.7 compared with starting value of 18.1 ± 7.0 in 
patients treated with FAE and to 6.7 ± 4.5 compared to starting value of 14.5 ± 
3.0 in patients treated with MTX. The absolute difference between groups (FAE 
vs. MTX) in the mean values was 1.4 (95%CI: 2.0; 4.7) and wasn’t statistically sig-
nificant (p = 0.417). In the remaining two double-blind studies the efficacy and 
safety of Fumaderm was assessed against the placebo. One study shows that in 
psoriasis vulgaris population the mean PASI in FAE group decreased from 21.53 at 
baseline to 10.77, whereas in placebo group mean PASI has not changed (p< 0.0001) 
after 16 weeks of treatment. Moreover, the results of study in psoriatic arthritis 
population revealed that FAE significantly (p< 0.04) decrease joint pain compared 
to placebo. cOnclusiOns: The results revealed that FAE and MTX have similar 
clinical efficacy in the treatment of patients with moderate to severe psoriasis. 
Moreover, FAE is more effective than placebo in the treatment of psoriasis vulgaris 
and psoriatic arthritis.
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knoWledge and PercePTion of medical and Pharmacy STudenTS 
ToWard The uSage of Sunblock
Hadi H., Elkalmi R., Awadh A., Jamshed S., Al-Shami A.
International Islamic University Malaysia, Kuantan, Malaysia
Objectives: To evaluate the knowledge and perception of medical and phar-
macy students toward the usage of sunblock as skin protection against ultraviolet 
(UV). MethOds: This cross-sectional study was conducted among the undergradu-
ate final year medical and pharmacy students at the International Islamic University 
Malaysia (IIUM). Validated questionnaire were used to collect the data. The question-
naires were distributed to 134 students from medicine and 100 pharmacy students. 
Descriptive and inferential statistics are used whenever appropriate. Results: 
Overall, 161 participants out of a total of 234 completed the questionnaire with 
101 medical students (75.4%) and 60 pharmacy students (60.0%). Majority of the 
respondents were female 64 (63.4%) and 37 (36.6%) were male. The median of knowl-
edge scores of the final year medical students was significantly lower than the 
final year pharmacy students (p< 0.01). There is no significant differnce between 
the knowledge of the female and male students (Mann Whitney U Test value = 
0.27, p< 0.01). This study reported that 24 (39.3 %) of pharmacy students were influ-
enced by the media to use sunblock whereas 35 (34.7%) of medical students had the 
highest influence from friends to use sunblock. However, this study showed there 
was no significant difference in the perception of pharmacy and medical studnets 
p= 0.020. cOnclusiOns: In conclusion, the knowledge of pharmacy students is 
significantly higher than the knowledge of medical students had on the usage of 
sunblock. Both medical and pharmacy students have the same level of perception 
towards the usage of sunblock.
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Smith & Nephew Biotherapeutics, Fort Worth, TX, USA
Objectives: Venous leg ulcers (VLUs) are a debilitating condition for patients with 
venous insufficiency. Compression therapy is the standard care for treatment of 
VLU; however the success rate is approximately 50% at 6 months. Clinical trials 
with cellular/tissue derived products (CTPs) have shown promising efficacy for 
the treatment of VLU. The objective was to identify patient and clinical character-
istics in the VLU population and examine patterns of CTP utilization. MethOds: 
Retrospective, de-identified electronic medical records from 2007-2013 were 
extracted from the Intellicure Limited Data Set (I-LDS). The I-LDS extracts records 
from 96 hospital-based outpatient wound centers. Patient, wound and encounter 
level characteristics were examined. CTPs of interest included extracellular matrix 
(ECM), human skin equivalent (HSE), and living skin equivalent (LSE). Results: 
A total of 9,091 patients, 25,734 wounds, and 222,666 encounters for VLU were 
identified. The majority of patients was male (50.5%), Caucasian (74.1%), and 
reported Medicare as their primary insurance (53.4%). The average age was 68.9 
(SD= 14.6) and the average number of physician visits was 17.7 (SD= 22.5). The mean 
wound surface area was 20.1cm2 (SD= 83.4). The overall average wound duration 
was 5.8 months (SD= 26.7). Of the 25,734 wounds, approximately 7.1% received 
ECM (3.4%), HSE (3.5%), or LSE (0.2%). The average number of applications for ECM 
was 2.7 (SD= 2.8), 0.6 (SD= 1.3) for HSE, and 3.1 (SD= 3.3) for LSE. Wounds treated 
with CTPs were, on average, several months older: 12.5, 13.7, and 11.1 months for 
ECM, HSE, and LSE, respectively. Overall average wound treatment time was 2.9 
months (SD= 4.8). However, treatment time was substantially longer with CTP 
utilization with an average time of 9.6, 9.7, and 7.5 months for ECM, HSE, and LSE, 
respectively. cOnclusiOns: CTP utilization was relatively low within outpatient 
wound centers. Results from this analysis indicate that health care providers are 
using CTPs on older, more difficult-to-heal VLUs.
